|
Mutation Information
|
Mutation Site
|
M230I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Country
|
Russia |
Literature Information
|
PubMed PMID
|
33136751
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
Journal of acquired immune deficiency syndromes (1999) |
|
Title
|
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. |
|
Author
|
Rizzardini G,Overton ET,Orkin C,Swindells S,Arasteh K,Górgolas Hernández-Mora M,Pokrovsky V,Girard PM,Oka S,Andrade-Villanueva JF,Richmond GJ,Baumgarten A,Masiá M,Latiff G,Griffith S,Harrington CM,Hudson KJ,St Clair M,Talarico CL,Patel P,Cutrell A,Van Eygen V,D'Amico R,Mrus JM,Wu S,Ford SL,Chow K,Roberts J,Wills A,Walters N,Vanveggel S,Van Solingen-Ristea R,Crauwels H,Smith KY,Spreen WR,Margolis DA |
|
Evidence
|
In ATLAS, there were 4 CVFs in the CAR arm, 3 of whom had reverse transcriptase mutations (M184I; M184V + G190S; and M230M/I) detected in HIV-1 RNA samples from 1 participant each, and 1 had no mutations.
|
|
|
HIV Mutation Detail Information